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People in the United Kingdom are consuming more than four times as many antidepressants 
as they were two decades ago (1). Despite this, we still do not fully understand the effects of 
these drugs, nor can we be confident about their risk-benefit ratio. 
Unresolved issues include the nature and frequency of potential serious adverse effects such 
as self-harming or suicidal actions, suicidal ideation and aggression.  In the linked paper, 
Sharma et al use Clinical Study Reports (CSRs) to explore these adverse effects. CSRs are 
prepared by pharmaceutical companies for the purpose of obtaining marketing authorisation. 
There are guidelines about contents and presentation of CSR’s (2) but no mandatory 
requirements. Consequently, although CSRs usually contain more data than published articles 
(3), the level of detail varies. Moreover, there may be differences between what is reported in 
the body of the CSR and data contained in appendices, such as individual patient listings of 
adverse events or narratives of serious adverse events.   
Sharma et al’s analysis of CSRs reveals misrepresentation of adverse events.  Comparing the 
‘results’ reported in CSRs with data from  individual patient listings or patient narratives 
revealed misclassification of deaths on antidepressants, and misrepresentation of suicidal 
events. More than half of the suicide attempts and instances of suicidal ideation were coded 
as ‘emotional lability’ or ‘worsening of depression,’ for example. Summary reports published 
on Eli Lilly’s website were found to be even more incomplete, listing only 10% of the suicide 
attempts revealed in the corresponding CSRs, and no instances of suicidal ideation. 
Over half of the CSRs selected by Sharma et al had no individual patient listings, this data 
having been withheld. This begs the question of how many more adverse events would have 
been revealed if individual patient listings were available for all trials, and raises concerns 
about why this information is allowed to be withheld.  
The current review is consistent with other evidence pointing to an increase in suicidal 
behaviour and ideation among children and adolescents taking selective serotonin reuptake 
inhibitors (SSRIs) (4). The paper by Sharma et al is the first large-scale, quantitative analysis 
to demonstrate an increase in aggressive behaviour in this age group. The analysis did not 
detect an increase in suicide, suicide attempts, suicidal ideation or aggression in adults and 
meta-analyses of data on adults remains conflicting (5; 6). Early case reports, published 
  
before the issue became controversial, document occurrence of these effects in adults, 
however, and also provide evidence as to the mechanism of these effects. These reports 
describe a state of agitation, somewhat similar to the akathisia produced by antipsychotics, 
associated with intense and violent suicidal preoccupation (7). However, as Sharma et al 
demonstrate, recording of ‘akathisia’ in antidepressant trials remains inconsistent and 
unreliable, hence we have little idea of the frequency of this effect. 
Although ‘activation’ effects (or akathisia) are recognized, there is little acknowledgement 
that antidepressants have mind-altering properties that are independent of their supposed 
effects on underlying mental disorders. One study revealed various changes to emotions and 
behaviour in patients taking antidepressants, which were associated with suicidal ideation (8). 
Evidence suggests there can be severe and sometimes prolonged withdrawal syndromes (9). 
With some exceptions (10), however, we lack the detailed exploration through animal 
behaviour and healthy volunteer studies that might clarify the range, nature and duration of 
the alterations that antidepressants induce.  
Despite their widespread use, antidepressants are only modestly more effective than placebo 
in trials of depression. Measures of global clinical improvement suggest the difference is not 
clinically relevant or even detectable (11). Moreover, placebo-controlled studies do not 
distinguish whether the effects of a drug are attributable to the targeting of putative 
underlying mechanisms, or a consequence of the drug’s mind-altering effects. The blunting 
of emotions produced by SSRIs may directly affect depression rating scale scores, for 
example, and their psychoactive and physical effects may influence patient expectations, 
promoting an amplified placebo effect (12).  
With doubts about the efficacy and effectiveness of antidepressants, and evidence that they 
can produce such serious adverse reactions as suicidal and aggressive tendencies, regulators 
and the public need access to more comprehensive and reliable data. The results reported in 
CSRs, on which decisions about market authorization are based, are likely to underestimate 
the extent of drug-related harms. We need access to original data from trials, but we also 
need more research that addresses the whole range of antidepressant-induced behavioural, 
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